NCT07058545View on ClinicalTrials.gov

A Study of CJC-1134-PC Injection in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

PHASE3CompletedINTERVENTIONAL
Enrollment

474

Participants

Timeline

Start Date

April 16, 2021

Primary Completion Date

February 20, 2023

Study Completion Date

February 20, 2023

Conditions
Type 2 Diabetes Mellitus - Poor Control
Interventions
DRUG

CJC-1134-PC Injection

Double-blind Treatment Period: 0.2ml (2mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)

DRUG

Placebo

Double-blind Treatment Period: 0.2ml (0mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.

INDUSTRY